23andMe, the DNA testing company that turns saliva into in-depth genetic analysis, is raising $200 million in funding led by Sequoia Capital, sources close to the situation confirmed to Business Insider.
ADVERTISEMENT
23andMe gets $200 million in funding to bring its genetic testing to the masses
The company is worth $1.5 billion just months after overcoming hurdles from the US Food and Drug Administration.
ADVERTISEMENT
In 2013, the US Food and Drug Administration (FDA) barred the company from sending any data related to health to customers, over concerns that the company misrepresented genetic tests as medical advice. This prevented the company from providing information about things like a customer's risk for developing a certain type of cancer, which was one of its major products.
The company started selling the tests again in 2015 with the FDA's approval, and in April 2017, the FDA officially authorized 23andMe to market its direct-to-consumer tests for 10 different medical diseases and conditions, including Parkinson's and Alzheimer's.
23andMe declined to comment.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
10 best airports in Africa in 2024
10 most expensive cities in Africa in 2024
Illegal money changers adapt to Zimbabwe's ZiG currency rollout
Zimbabwe's ZiG currency printing contingent on reserve sufficiency
The global workforce is set to collapse without Africa
500 millionaires fall off in Kenya - here’s why
Top 10 African countries with the most centi-millionaires in 2024
7 most influential Africans in the world 2024 -TIME